H P Brunner-La Rocca 1, M D Esler, G L Jennings, D M Kaye Affiliations expand
Abstract Aims: To investigate whether strong cardiac sympathetic activity contributes primarily to sudden death or to worsening heart failure, and to determine the relationship of the size of cardiac noradrenaline stores to the mode of death. Methods and results: The study population comprised 116 patients with congestive heart failure (ejection fraction 19+/-7%) and a mean follow-up of 18+/-19 months. Cardiac sympathetic nervous function was measured using coronary sinus blood sampling and noradrenaline isotope dilution methodology. Cardiac sympathetic activity was estimated from cardiac noradrenaline spillover, and noradrenaline stores from the overflow of the tritiated noradrenaline metabolite [(3)H]dihydroxyphenylglycol, which is produced by monoamine oxidase inside nerve endings. Small cardiac noradrenaline stores (below median) predicted death from worsening heart failure (hazard ratio=4.18, P<0.05), particularly if cardiac noradrenaline spillover was elevated (hazard ratio=2.36 per tertile, P<0.01), indicating progression of disease associated with defective sympathetic innervation. In contrast, large stores (hazard ratio=2.81, P<0.05), especially if coupled with increased noradrenaline spillover (hazard ratio=1.64 per tertile, P<0.05), were related to sudden death. Conclusion: High cardiac sympathetic activity is a risk factor for sudden death, particularly in the presence of intact cardiac sympathetic innervation. Conversely, progression of myocardial disease and heart failure is closely associated with depletion of sympathetic nerves in the heart, especially if rates of noradrenaline release paradoxically remain high.
Copyright 2001 The European Society of Cardiology.
A sympathetic heart and the art of dying.Coats AJ.Eur Heart J. 2001 Jul;22(13):1069-71. doi: 10.1053/euhj.2000.2763.PMID: 11428846 No abstract available.
Increased central nervous system monoamine neurotransmitter turnover and its association with sympathetic nervous activity in treated heart failure patients.Lambert GW, Kaye DM, Lefkovits J, Jennings GL, Turner AG, Cox HS, Esler MD.Circulation. 1995 Oct 1;92(7):1813-8. doi: 10.1161/01.cir.92.7.1813.PMID: 7545554
Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake.Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD.Circulation. 1993 Jul;88(1):136-45. doi: 10.1161/01.cir.88.1.136.PMID: 8391399
Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure.Kaye DM, Lambert GW, Lefkovits J, Morris M, Jennings G, Esler MD.J Am Coll Cardiol. 1994 Mar 1;23(3):570-8. doi: 10.1016/0735-1097(94)90738-2.PMID: 8113536
Clinical application of noradrenaline spillover methodology: delineation of regional human sympathetic nervous responses.Esler M.Pharmacol Toxicol. 1993 Nov;73(5):243-53. doi: 10.1111/j.1600-0773.1993.tb00579.x.PMID: 8115306 Review.
New Approaches in the Management of Sudden Cardiac Death in Patients with Heart Failure-Targeting the Sympathetic Nervous System.Kiuchi MG, Nolde JM, Villacorta H, Carnagarin R, Chan JJS, Lugo-Gavidia LM, Ho JK, Matthews VB, Dwivedi G, Schlaich MP.Int J Mol Sci. 2019 May 16;20(10):2430. doi: 10.3390/ijms20102430.PMID: 31100908. Review.
See all similar articles